The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.
Sangamo said ...
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.